当前位置： SCI文献检索 > GYNECOLOGIC ONCOLOGY期刊下所有文献 > Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.

Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.

Abstract：

:A 20 year old with recurrent low-grade serous carcinoma (LGSC) is discussed. The differential diagnosis, pathology, epidemiology, treatment options are discussed. Focus on the molecular pathways of LGSC and the implications of the diagnosis on fertility are highlighted.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Cohn DE,Backes FJ,Wallbillich JJ,Bixel K,Crafton SM,Neff R,ElNaggar AC,Smith B,Suarez AA

doi

10.1016/j.ygyno.2017.01.023

subject

Has Abstract

pub_date

2017-03-01 00:00:00

pages

451-455

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(17)30067-7

journal_volume

144

pub_type

杂志文章

相关文献

GYNECOLOGIC ONCOLOGY文献大全
  • Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.

    abstract：OBJECTIVE:The objective of this study was to determine the efficacy and hematologic toxicity of salvage chemotherapy in patients with recurrent ovarian cancer following high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT). METHODS:A retrospective analysis of 19 Massachusetts General Hospital c...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1999.5710

    authors： Cook S,Penson R,Duska L,Nikrui N,Goodman A,Fuller A,Seiden M

    更新日期：2000-04-01 00:00:00

  • Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

    abstract：OBJECTIVE:This trial determined the efficacy and tolerability of sorafenib and weekly topotecan in patients with platinum-resistant ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC). METHODS:Primary endpoints were maximum tolerated dose of sorafenib with weekly topotecan (phase I) and response rate (phase...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2011.08.033

    authors： Ramasubbaiah R,Perkins SM,Schilder J,Whalen C,Johnson CS,Callahan M,Jones T,Sutton G,Matei D

    更新日期：2011-12-01 00:00:00

  • Papillary villoglandular carcinoma of the cervix.

    abstract：:Three cases of papillary villoglandular carcinoma of the cervix are presented. Each patient was multiparous and presented with abnormal vaginal bleeding. The mean age at presentation was 35 years (range 28-42 years). All patients were staged as FIGO IB and underwent radical Wertheim hysterectomy and bilateral pelvic l...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(90)90437-p

    authors： Hopson L,Jones MA,Boyce CR,Tarraza HM Jr

    更新日期：1990-11-01 00:00:00

  • Sclerosing stromal tumor and bilateral teratomas: an unusual association.

    abstract：:Sclerosing stromal tumor is an uncommon ovarian neoplasm that has only recently been defined and distinguished from fibrothecoma. This case report describes a 17-year-old patient who presented with a large sclerosing stromal tumor and a smaller mature teratoma in the left ovary. Eighteen months later, an immature tera...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(85)90261-6

    authors： Valente PT,Carr RF,Hanjani P

    更新日期：1985-06-01 00:00:00

  • Alternative medicine in gynecologic oncology: A case report.

    abstract：:A patient with Stage IIB squamous cell cancer of the cervix presented 10 days into her primary radiation therapy with neutropenic fever and diarrhea requiring hospitalization and delay in treatment. The patient's history revealed extensive use of alternative therapies including potential toxic botanicals. This case ra...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2000.5743

    authors： von Gruenigen VE,Hopkins MP

    更新日期：2000-04-01 00:00:00

  • Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.

    abstract：:We have previously reported an overall response rate of 41% and a median survival duration of 14 months in a series of 49 patients with metastatic or recurrent endometrial carcinoma treated by a combination of etoposide, 5-fluorouracil, and cisplatin. In order to increase response rate and survival duration, doxorubic...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1006/gyno.1997.4749

    authors： Pierga JY,Diéras V,Beuzeboc P,Dorval T,Palangié T,Jouve M,Scholl SM,Garcia-Giralt E,Pouillart P

    更新日期：1997-08-01 00:00:00

  • Reconstructive surgery following resection of primary vulvar cancers.

    abstract：OBJECTIVE:This study describes the surgical treatment and follow-up of 213 patients with primary vulvar cancer; particular attention is given to reconstructive surgical procedures. METHODS:The clinical and pathological parameters of the patients were recorded according to standardized procedures, and the data concerni...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2005.05.031

    authors： Weikel W,Hofmann M,Steiner E,Knapstein PG,Koelbl H

    更新日期：2005-10-01 00:00:00

  • A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.

    abstract：OBJECTIVE:Approximately 2 million women worldwide are infected with high-risk human papillomaviruses (HPV), resulting in a substantial risk for the development of invasive lower genital malignancies. This study was undertaken to determine the effects of vaccination with a protein encoding a bacterial heat shock protein...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2007.05.038

    authors： Roman LD,Wilczynski S,Muderspach LI,Burnett AF,O'Meara A,Brinkman JA,Kast WM,Facio G,Felix JC,Aldana M,Weber JS

    更新日期：2007-09-01 00:00:00

  • Compliance with research standards within gynecologic oncology fellowship: A Gynecologic Oncology Fellowship Research Network (GOFRN) study.

    abstract：OBJECTIVES:Participation in clinical and basic science research is emphasized in gynecologic oncology training. We sought to identify trends in adherence to expected research practices and reasons for non-adherence among gynecologic oncology fellows. METHODS:An anonymous 31-question online survey assessing academic be...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2017.06.034

    authors： Moulton LJ,Michener CM,Levinson K,Cobb L,Tseng J,Jernigan A

    更新日期：2017-09-01 00:00:00

  • Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study.

    abstract：OBJECTIVE:Conization aims to remove pre-neoplastic lesions of the uterine cervix. Several techniques for conization have been compared, but evidence regarding the most effective therapeutic option is scant. Here, we aimed to compare the recurrence rate following laser conization and loop electrosurgical excision proced...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2020.08.025

    authors： Bogani G,DI Donato V,Sopracordevole F,Ciavattini A,Ghelardi A,Lopez S,Simoncini T,Plotti F,Casarin J,Serati M,Pinelli C,Valenti G,Bergamini A,Gardella B,Dell'acqua A,Monti E,Vercellini P,Fischetti M,D'Ippolito G,Agu

    更新日期：2020-12-01 00:00:00

  • Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study.

    abstract：OBJECTIVE:The aim of this study was to investigate the clinical and pathological characteristics of uterine clear cell carcinoma (UCCC) and the treatment of this disease in relation to patient outcomes. METHODS:The clinicopathological data for and the management of all patients with UCCC who presented between 1991 and...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2014.07.005

    authors： Hsu KF,Chou HH,Huang CY,Fu HC,Chiang AJ,Tsai HW,Chen JR,Cheng WF,Ke YM,Chang CC,Chen TH,Lin SH,Ho CM

    更新日期：2014-09-01 00:00:00

  • Survival probability in ovarian clear cell adenocarcinoma.

    abstract：OBJECTIVE:The aim of this study was to evaluate the 5-year survival probability (SP) of patients treated for ovarian clear cell adenocarcinoma (OCCA) at a single tertiary institution and to compare it to the 5-year SP of patients with other histologic subtypes of epithelial ovarian cancer. METHODS:Sixty-four patients ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1999.5445

    authors： Kennedy AW,Markman M,Biscotti CV,Emery JD,Rybicki LA

    更新日期：1999-07-01 00:00:00

  • Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.

    abstract：OBJECTIVES:Pegylated liposomal doxorubicin is one of the preferred alternatives for ovarian cancer patients with early relapse (<6 months) and taxane/carboplatin for late relapse (>12 months), but the optimal therapy for the partially platinum-sensitive (6-12 months) population has not been defined. This single-arm pha...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.ygyno.2009.04.037

    authors： Power P,Stuart G,Oza A,Provencher D,Bentley JR,Miller WH Jr,Pouliot JF

    更新日期：2009-09-01 00:00:00

  • Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States.

    abstract：INTRODUCTION:Non-Hispanic black women are less often diagnosed with endometrial cancer than are non-Hispanic white women, but are more likely to die of their disease. Reasons for this disparity in outcome are not well understood. METHODS:The Surveillance, Epidemiology, and End-Results Program data were used to sample ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.11.041

    authors： Trimble EL,Harlan LC,Clegg LX,Stevens JL

    更新日期：2005-03-01 00:00:00

  • Human immunodeficiency virus infection and invasive cervical cancer in South Africa.

    abstract：PURPOSE:The goal of this study was to determine whether South African HIV-seropositive women with invasive cervical cancer present with disease that is more advanced than that of HIV-seronegative women and whether degree of immunosuppression affects the extent of disease at initial presentation. METHODS:This study is ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.2000.5775

    authors： Lomalisa P,Smith T,Guidozzi F

    更新日期：2000-06-01 00:00:00

  • The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.

    abstract：OBJECTIVE:In advanced ovarian cancer, patients cytoreduced to no visible disease appear to have improved survival compared to patients with visible residual tumor < or = 10 mm. It remains unresolved whether this is due to better chemotherapy response and/or simply "re-setting the clock," such that patients with less re...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.10.022

    authors： Eisenhauer EL,Abu-Rustum NR,Sonoda Y,Aghajanian C,Barakat RR,Chi DS

    更新日期：2008-02-01 00:00:00

  • A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.

    abstract：OBJECTIVES:Ovarian cancer remains a leading cause of death in women and development of new therapies is essential. Second mitochondria derived activator of caspase (Smac) has been described to sensitize for apoptosis. We have explored the proapoptotic activity of a small molecule mimic of Smac/DIABLO on ovarian cancer ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2007.01.011

    authors： Petrucci E,Pasquini L,Petronelli A,Saulle E,Mariani G,Riccioni R,Biffoni M,Ferretti G,Benedetti-Panici P,Cognetti F,Scambia G,Humphreys R,Peschle C,Testa U

    更新日期：2007-05-01 00:00:00

  • A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer.

    abstract：OBJECTIVE:Use of in vitro chemoresponse assays for informing effective treatment selection is a compelling clinical question and a topic of debate among oncologists. A prospective study was conducted evaluating the use of a chemoresponse assay in recurrent ovarian cancer patients. METHODS:Women with persistent or recu...

    journal_title：Gynecologic oncology

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.ygyno.2013.08.009

    authors： Rutherford T,Orr J Jr,Grendys E Jr,Edwards R,Krivak TC,Holloway R,Moore RG,Puls L,Tillmanns T,Schink JC,Brower SL,Tian C,Herzog TJ

    更新日期：2013-11-01 00:00:00

  • Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid.

    abstract：OBJECTIVE:Resveratrol (Res) is known to inhibit adhesion of numerous malignancies though its effect on an adherence of ovarian cancer cells to peritoneal mesothelium remains undefined. METHODS:To address this issue, ovarian cancer cells (A2780, OVCAR-3, SKOV-3) were subjected to Res (10, 50, 100 μM), and then their ad...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.06.022

    authors： Mikuła-Pietrasik J,Sosińska P,Książek K

    更新日期：2014-09-01 00:00:00

  • Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment.

    abstract：:To identify FIGO I ovarian cancer patients at high risk, prognostic values of quantitative pathological features (volume percentage of epithelium, mitotic activity index, mean (MNA) and standard deviation of nuclear profile area, and volume-weighted mean nuclear volume (MNV) have been investigated in comparison with c...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1006/gyno.1997.4884

    authors： Brugghe J,Baak JP,Wiltshaw E,Brinkhuis M,Meijer GA,Fisher C

    更新日期：1998-01-01 00:00:00

  • Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer.

    abstract：OBJECTIVES:To assess the utility of tumor diameter (TD) for predicting lymphatic dissemination (LD) and determining need for lymphadenectomy following diagnosis of endometrioid endometrial cancer. METHODS:Patients diagnosed with stage I-III endometrioid endometrial cancer during 2003-2013 who underwent pelvic or para-...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2016.02.017

    authors： Cox Bauer CM,Greer DM,Kram JJF,Kamelle SA

    更新日期：2016-05-01 00:00:00

  • Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

    abstract：OBJECTIVE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediates apoptosis via binding to death receptors and enhances the anti-tumor effect of conventional cancer therapies. We evaluated the efficacy of TRA-8, an agonistic antibody to DR5, combined with docetaxel and carboplatin in vitro in an intrap...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2010.11.046

    authors： Bevis KS,McNally LR,Sellers JC,Della Manna D,Londoño Joshi A,Amm H,Straughn JM Jr,Buchsbaum DJ

    更新日期：2011-04-01 00:00:00

  • Prognostic value of CA 125 in advanced ovarian cancer.

    abstract：:CA 125 was measured during early chemotherapy in 121 patients with FIGO stage III or IV ovarian cancer to investigate if the antigen could be used as a prognostic parameter. CA 125 was determined before the start of chemotherapy and 1 month after the first, second, and third course. The antigen level before the start ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(92)90043-i

    authors： Mogensen O

    更新日期：1992-03-01 00:00:00

  • Merkel cell carcinoma of the Bartholin's gland.

    abstract：BACKGROUND:There are a few cases of "small cell neuroendocrine carcinoma" of the Bartholin's gland as well as Merkel cell carcinoma of the vulva reported in the gynecologic oncology literature, most with aggressive clinical behavior. Merkel cells were originally described in the epidermis with neuroendocrine properties...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.12.064

    authors： Khoury-Collado F,Elliott KS,Lee YC,Chen PC,Abulafia O

    更新日期：2005-06-01 00:00:00

  • Vascular endothelial growth factor (VEGF) and ovarian carcinoma cell supernatant activate signal transducers and activators of transcription (STATs) via VEGF receptor-2 (KDR) in human hemopoietic progenitor cells.

    abstract：OBJECTIVE:To investigate the STATs signaling pathway activated by VEGF in human hemopoietic progenitor cells. METHODS:CD34(+) hemopoietic progenitor cells, which isolated from umbilical cord blood, were treated with VEGF or culture supernatant of ovarian carcinoma cell line which could secrete large amount of VEGF, ph...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2004.03.038

    authors： Ye F,Chen HZ,Xie X,Ye DF,Lu WG,Ding ZM

    更新日期：2004-07-01 00:00:00

  • Racial disparities in survival in malignant germ cell tumors of the ovary.

    abstract：OBJECTIVE:To investigate racial disparities with respect to adjuvant treatment and survival in patients presenting with malignant ovarian germ cell tumors (OGCT). METHODS:The National Cancer Database (NCDB) was used to identify women diagnosed with OGCT. Demographic data were abstracted, including stratification by ra...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2016.01.006

    authors： Hinchcliff E,Rauh-Hain JA,Clemmer JT,Diver E,Hall T,Stall J,Growdon W,Clark R,Schorge J

    更新日期：2016-03-01 00:00:00

  • Mutations in TAP genes are common in cervical carcinomas.

    abstract：OBJECTIVE:To determine whether squamous cervical cancers exhibit mutations or deletions in MHC class I genes or transport-associated protein (TAP) genes. METHODS:Polymerase chain reaction based protocols were used to examine HLA class I and TAP genes in a panel of cervical tumours, using DNA from corresponding blood s...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2003.11.037

    authors： Fowler NL,Frazer IH

    更新日期：2004-03-01 00:00:00

  • Epithelial ovarian carcinoma in patients with intersex disorders: the role of pituitary gonadotropins in ovarian tumorigenesis.

    abstract：:The common epithelial tumors of the human ovary have rarely been found in the gonads of intersex patients with gonadal dysgenesis or true hermaphroditism. This report describes a patient with ovarian serous cystadenocarcinoma and mixed gonadal dysgenesis (45,X/46,XY) and reviews other reported cases. Intersex patients...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/0090-8258(86)90306-9

    authors： Miller DS,Teng NN,Ballon SC

    更新日期：1986-07-01 00:00:00

  • Metachronous metastases from renal cell carcinoma to uterine cervix and vagina: case report and review of literature.

    abstract：BACKGROUND:Although renal cell carcinoma (RCC) is characterized with unpredictable clinical presentation, multiple genital tract metastases are still surprising and mode of spread is obscure. CASE:We report a case of RCC metastases to uterine cervix and vagina 1 year after radical nephrectomy in a 19-year-old virgin. ...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章,评审

    doi：10.1016/j.ygyno.2005.06.004

    authors： Bozaci EA,Atabekoğlu C,Sertçelik A,Unlü C,Ortaç F

    更新日期：2005-10-01 00:00:00

  • Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.

    abstract：OBJECTIVE:To determine whether chemotherapy-induced neutropenia (C-iN) is associated with improved survival in a population of primary advanced ovarian cancer and peritoneal carcinoma patients treated with a carboplatin plus paclitaxel chemotherapy backbone. METHODS:A post-hoc exploratory analysis of Gynecologic Oncol...

    journal_title：Gynecologic oncology

    pub_type： 杂志文章

    doi：10.1016/j.ygyno.2014.03.013

    authors： Tewari KS,Java JJ,Gatcliffe TA,Bookman MA,Monk BJ

    更新日期：2014-06-01 00:00:00